Actively Recruiting

Age: 18Years - 70Years
FEMALE
NCT06754059

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

Led by zhangjie · Updated on 2025-01-01

60

Participants Needed

1

Research Sites

343 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A single-arm, multicenter, real-world observational study of pyrotinib combined with trastuzumab for maintenance therapy after first-line TH (P) therapy for HER2+ABC

CONDITIONS

Official Title

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

Who Can Participate

Age: 18Years - 70Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female aged 18 to 70 years old
  • Pathologically confirmed HER2-positive invasive breast cancer
  • Imaging confirms recurrent or metastatic breast cancer
  • Recurrence or metastasis more than 1 year after trastuzumab treatment or newly diagnosed stage IV breast cancer
  • ECOG performance status 0-1
  • Expected survival of at least 6 months
  • Normal major organ function
  • Blood routine: ANC ≥1.5×10⁹/L; PLT ≥90×10⁹/L; Hb ≥90 g/L
  • Blood biochemistry: TBIL ≤1.5×ULN; ALT and AST ≤2×ULN (≤5×ULN if liver metastases); BUN and creatinine ≤1.5×ULN; creatinine clearance ≥50 mL/min
  • Heart ultrasound: LVEF ≥50%
  • Investigator believes subject may benefit
  • Voluntary participation with signed informed consent
Not Eligible

You will not qualify if you...

  • Brain metastases confirmed by head MRI or CT
  • Conditions affecting oral medication intake (e.g., gastrointestinal surgery history, inability to swallow, chronic diarrhea, intestinal obstruction)
  • Allergy to study drugs or excipients
  • Mental illness or psychotropic substance abuse preventing cooperation
  • Pregnant or breastfeeding women
  • Participation in other clinical trials within 4 weeks
  • Considered unsuitable for inclusion by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fujian Union Medical College Hospital

Fuzhou, Fujian, China, 350000

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here